DrugDashboards

Mometasone Furoate Monohydrate

Mometasone Furoate Monohydrate · MOMETASONE FUROATE MONOHYDRATE 50 ug/1 · Spray, Metered · Nasal · Aurobindo Pharma Limited

NDC 59651-0402-17 · 1 BOTTLE, SPRAY in 1 CARTON / 120 SPRAY, METERED in 1 BOTTLE, SPRAY · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 10% over the past year, to $1.59 per gram. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$1.00$2.00$3.00Aug 2024Sep 2026$1.59
26 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$120.00
Reported to Texas DSHS · 2026 annual filing · Aurobindo Pharma Usa, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$211,490
5,171 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for mometasone furoate monohydrate (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA215878
TE code
AB
Approval date
Mar 18, 2024
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Mometasone Furoate Monohydrate (Spray, Metered)

LabelerStrengthFirst seenLast seen
Amazon.com Services LLCMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
Aurobindo Pharma LimitedMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
Cvs Woonsocket Prescription Center, IncorporatedMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
HyVee IncMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
Rite Aid CorporationMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
Topco Associates LLCMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026
Walgreen CompanyMOMETASONE FUROATE MONOHYDRATE 50 ug/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Mometasone Furoate Monohydrate — NDC 59651-0402-17," retrieved September 3, 2026, https://drugdashboards.com/drug/59651040217.

Free to cite with attribution — see how the data is put together.